Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019050780) COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/050780 International Application No.: PCT/US2018/048995
Publication Date: 14.03.2019 International Filing Date: 31.08.2018
IPC:
A61K 39/395 (2006.01) ,A61K 38/03 (2006.01) ,A61K 47/22 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
03
Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
06
Organic compounds
22
Heterocyclic compounds
Applicants:
CHU, Lin [US/US]; US (US)
TOUSSAINT, Nathalie, Y. [US/US]; US (US)
XIAO, Dong [US/US]; US (US)
VACHAL, Petr [US/US]; US (US)
KASHI, Ramesh, S. [US/US]; US (US)
BAK, Annette [US/SE]; SE (US)
MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue Rahway, New Jersey 07065-0907, US
Inventors:
CHU, Lin; US
TOUSSAINT, Nathalie, Y.; US
XIAO, Dong; US
VACHAL, Petr; US
KASHI, Ramesh, S.; US
BAK, Annette; SE
Common
Representative:
MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue Rahway, New Jersey 07065-0907, US
Priority Data:
62/554,13405.09.2017US
Title (EN) COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS
(FR) COMPOSÉS POUR LA RÉDUCTION DE LA VISCOSITÉ DE FORMULATIONS BIOLOGIQUES
Abstract:
(EN) The present invention relates to pegylated amino acid compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3A, R3B and n are as defined herein. The present invention also relates to compositions which comprise a pegylated amino acid compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in combination with a high concentration of an active biological ingredient (ABI). In embodiments of the invention, the ABI is an anti-PD-1 antibody or antigen binding fragment thereof that specifically binds human programmed death receptor 1 (PD-1). The invention further relates to methods for lowering the viscosity of an aqueous solution of a pharmaceutical composition comprising adding a compound of the invention to the solution. The invention also provides methods for treating a pathological disease or condition, such as cancer, by administering to a subject in need of such treatment a therapeutically effective amount of a pharmaceutical composition of the invention.
(FR) La présente invention concerne des composés acides aminés pégylés de formule (I) et des sels pharmaceutiquement acceptables de ceux-ci, où X, R1, R2, R3A, R3B et n sont tels que définis dans la présente invention. La présente invention concerne également des compositions qui comprennent un composé acide aminé pégylé selon l'invention, ou un sel pharmaceutiquement acceptable de celui-ci, et un support pharmaceutiquement acceptable, en association avec une concentration élevée d'un principe actif biologique (ABI). Dans des modes de réalisation de l'invention, l'ABI est un anticorps anti-PD-1 ou un fragment de liaison à l'antigène de celui-ci qui se lie spécifiquement au récepteur-1 de mort cellulaire programmée (PD-1) humain. L'invention concerne en outre des procédés pour l'abaissement de la viscosité d'une solution aqueuse d'une composition pharmaceutique comprenant l'ajout d'un composé selon l'invention à la solution. L'invention concerne également des méthodes de traitement d'une maladie ou d'un état pathologique, tels que le cancer, par l'administration à un sujet qui a besoin d'un tel traitement d'une quantité thérapeutiquement efficace d'une composition pharmaceutique selon l'invention.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)